Understanding clinical risk decision making regarding development of depression during interferon-alpha treatment for hepatitis-C: A qualitative interview study
Files in This Item:
|Hepgul_&_Kodate_et_al_2012.pdf||491.3 kB||Adobe PDF||Download|
|Title:||Understanding clinical risk decision making regarding development of depression during interferon-alpha treatment for hepatitis-C: A qualitative interview study||Authors:||Hepgul, Nilay
Anderson, Janet E.
|Permanent link:||http://hdl.handle.net/10197/4916||Date:||Dec-2012||Online since:||2013-11-12T09:42:57Z||Abstract:||Background: Hepatitis C virus (HCV) affects 170 million worldwide. Currently, around 30% of patients receiving interferon-alpha (IFN-α) treatment for HCV experience clinically significant depression. Effective and timely detection of depression is crucial to ensuring appropriate treatment and support. However, little is known about how clinical nurse specialists identify patients at risk of developing interferon-alpha-induced depression, and monitor those receiving antiviral treatment for the occurrence of depression.||Type of material:||Journal Article||Publisher:||Elsevier||Journal:||International Journal of Nursing Studies||Volume:||49||Issue:||12||Start page:||1480||End page:||1488||Copyright (published version):||2012 Elsevier Ltd.||Keywords:||Decision-making; Depression; Hepatitis C; Interferon-alpha; Nurse Clinicians||DOI:||10.1016/j.ijnurstu.2012.07.016||Language:||en||Status of Item:||Peer reviewed|
|Appears in Collections:||Social Policy, Social Work and Social Justice Research Collection|
Show full item record
Page view(s) 5080
This item is available under the Attribution-NonCommercial-NoDerivs 3.0 Ireland. No item may be reproduced for commercial purposes. For other possible restrictions on use please refer to the publisher's URL where this is made available, or to notes contained in the item itself. Other terms may apply.